These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 12914822)

  • 21. Learnings from over 25 years of PNH experience: the era of targeted complement inhibition.
    Heitlinger E
    Blood Rev; 2013 Dec; 27 Suppl 1():S1-6. PubMed ID: 24331206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complement and Bacterial Infections: From Molecular Mechanisms to Therapeutic Applications.
    Heesterbeek DAC; Angelier ML; Harrison RA; Rooijakkers SHM
    J Innate Immun; 2018; 10(5-6):455-464. PubMed ID: 30149378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strategies for targeting complement inhibitors in ischaemia/reperfusion injury.
    Dong J; Pratt JR; Smith RA; Dodd I; Sacks SH
    Mol Immunol; 1999; 36(13-14):957-63. PubMed ID: 10698350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacological effects on the complement system. Possibilities and limitations of anti-inflammatory therapy].
    Kirschfink M
    Dtsch Med Wochenschr; 1995 Aug; 120(31-32):1087-90. PubMed ID: 7641591
    [No Abstract]   [Full Text] [Related]  

  • 25. Therapeutic uses of recombinant complement protein inhibitors.
    Kalli KR; Hsu P; Fearon DT
    Springer Semin Immunopathol; 1994; 15(4):417-31. PubMed ID: 8153875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Roles of the complement system in human neurodegenerative disorders: pro-inflammatory and tissue remodeling activities.
    Gasque P; Neal JW; Singhrao SK; McGreal EP; Dean YD; Van BJ; Morgan BP
    Mol Neurobiol; 2002 Feb; 25(1):1-17. PubMed ID: 11890454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The complement system: an old story or target of new therapeutic approaches?].
    Heller A; Koch T
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2000 Apr; 35(4):207-13. PubMed ID: 10830072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endothelial targeting and enhanced antiinflammatory effects of complement inhibitors possessing sialyl Lewisx moieties.
    Mulligan MS; Warner RL; Rittershaus CW; Thomas LJ; Ryan US; Foreman KE; Crouch LD; Till GO; Ward PA
    J Immunol; 1999 Apr; 162(8):4952-9. PubMed ID: 10202042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the complement system.
    Marsh JE; Pratt JR; Sacks SH
    Curr Opin Nephrol Hypertens; 1999 Sep; 8(5):557-62. PubMed ID: 10541217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future.
    Risitano AM; Marotta S
    Semin Immunol; 2016 Jun; 28(3):223-40. PubMed ID: 27346521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Artificial surface-induced cytokine synthesis: effect of heparin coating and complement inhibition.
    Lappegård KT; Fung M; Bergseth G; Riesenfeld J; Mollnes TE
    Ann Thorac Surg; 2004 Jul; 78(1):38-44; discussion 44-5. PubMed ID: 15223398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroprotection from complement-mediated inflammatory damage.
    Kulkarni AP; Kellaway LA; Lahiri DK; Kotwal GJ
    Ann N Y Acad Sci; 2004 Dec; 1035():147-64. PubMed ID: 15681806
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Developments in anti-complement therapy; from disease to clinical trial.
    Harris CL; Pouw RB; Kavanagh D; Sun R; Ricklin D
    Mol Immunol; 2018 Oct; 102():89-119. PubMed ID: 30121124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ischemia/reperfusion injury: effect of simultaneous inhibition of plasma cascade systems versus specific complement inhibition.
    Duehrkop C; Rieben R
    Biochem Pharmacol; 2014 Mar; 88(1):12-22. PubMed ID: 24384116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic inhibition of the early phase of complement activation.
    Roos A; Ramwadhdoebé TH; Nauta AJ; Hack CE; Daha MR
    Immunobiology; 2002 Sep; 205(4-5):595-609. PubMed ID: 12396018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complement proteins and complement inhibitors in Alzheimer's disease.
    McGeer PL; McGeer EG
    Res Immunol; 1992; 143(6):621-4. PubMed ID: 1455053
    [No Abstract]   [Full Text] [Related]  

  • 37. Prevention of hyperacute rejection of pig-to-monkey cardiac xenografts by Chinese cobra venom factor.
    Chen G; Wang XM; Sun QY; Shen SQ; Guo H; Wang H; Chen LJ; Wu Y; Wang WY; Xiong YL; Wei QX; Chen S
    Transplant Proc; 2001; 33(7-8):3857-8. PubMed ID: 11750642
    [No Abstract]   [Full Text] [Related]  

  • 38. Reactions and side reactions to drugs.
    Rother U
    Prog Allergy; 1986; 39():123-33. PubMed ID: 3562461
    [No Abstract]   [Full Text] [Related]  

  • 39. Complement and biocompatibility.
    Mollnes TE
    Vox Sang; 1998; 74 Suppl 2():303-7. PubMed ID: 9704460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heparin treatment in pregnancy loss: Potential therapeutic benefits beyond anticoagulation.
    Girardi G
    J Reprod Immunol; 2005 Jun; 66(1):45-51. PubMed ID: 15949561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.